Investopedia: Better Margins Can't Hide Merck's Growth Challenges

In spite of pretty weak top-line results, pharma companies like Merck (NYSE: MRK ), Pfizer (NYSE: PFE ), and Bristol-Myers (NYSE: BMY ) ...

Investopedia: Pfizer Looking A Little Tired

At some point this bull market in all things health care will fade out, and I wonder if Pfizer (NYSE: PFE ) shares will maintain this sort ...

Investopedia: Wall Street Happy To Hum La AbbVie En Rose

For a business that seemed to be oft-maligned when it was still part of Abbott Labs (NYSE: ABT ), AbbVie (Nasdaq: ABBV ) has done pretty ...

Investopedia: Drugs Driving JNJ, With Slow Progress In Devices And Consumer

Another quarter is in the books, and not all that much has changed at healthcare giant Johnson & Johnson (NYSE: JNJ ). The company...

Investopedia: Amgen Puts Onyx Pharmaceuticals In Play

Funny how an unsolicited bid will suddenly alert Wall Street to the value of a strong biotech. While Onyx Pharmaceuticals (Nasdaq: ONXX )...

Investopedia: Alnylam Basking In Orphan Drug Attention

It's been a pretty wild ride for Alnylam (Nasdaq: ALNY ) shareholders, even by the elevated standards of biotechnology. Once thought t...

Investopedia: After A Big Rally, Pfizer Might Need Some Rest

Big Pharma has enjoyed an exceptional stretch of performance lately, reversing what had been a relatively rare period of underperformance ...

Investopedia: Amgen Chased By The Bubble

There are two relatively heated debates that bear directly on Amgen (Nasdaq: AMGN ) and its stock. First, is Amgen still really a biotech,...

Seeking Alpha: No News Becoming Bad News For Lexicon Pharmaceuticals

Normally you would think that having a differentiated and proprietary diabetes compound with solid supporting data would make a biotech re...